Trial tests new drug combo to fight rare bleeding disorder
NCT ID NCT03384277
Summary
This study compared two different drug combinations to eliminate harmful antibodies in patients with acquired hemophilia A, a rare bleeding disorder. 66 adult patients in China were randomly assigned to receive either a steroid with rituximab or a steroid with cyclophosphamide. The main goal was to see which combination was better at removing the antibodies and restoring normal blood clotting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED HEMOPHILIA A are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ethics Committee of Blood disease hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.